Cargando…

Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak: experience from an Italian skin cancer unit

Detalles Bibliográficos
Autores principales:	Quaglino, Pietro, Fava, Paolo, Brizio, Matteo, Marra, Elena, Rubatto, Marco, Merli, Martina, Tonella, Luca, Ribero, Simone, Fierro, Maria Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874884/ https://www.ncbi.nlm.nih.gov/pubmed/33533662 http://dx.doi.org/10.2217/fon-2020-0997

Ejemplares similares

Treatment of Advanced Metastatic Melanoma
por: Quaglino, Pietro, et al.
Publicado: (2021)

Clinical and Pathological Relevance of Drug-induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF/MEK Inhibitors
por: RAMONDETTA, Alice, et al.
Publicado: (2020)

Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study
por: Gullo, Giulia, et al.
Publicado: (2022)

Clinical evaluation of hydration index using a corneometer in metastatic melanoma patients treated with BRAF/MEK inhibitors: a prospective study
por: Amabile, Simone, et al.
Publicado: (2022)

Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials
por: Amabile, Simone, et al.
Publicado: (2021)

Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer
por: Rubatto, Marco, et al.
Publicado: (2023)

Melanoma Management during the COVID-19 Pandemic Emergency: A Literature Review and Single-Center Experience
por: Cariti, Caterina, et al.
Publicado: (2021)

Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications
por: Tonella, Luca, et al.
Publicado: (2021)

Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
por: Liberini, Virginia, et al.
Publicado: (2021)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Metastatic sebaceous cell carcinoma, review of the literature and use of electrochemotherapy as possible new treatment modality
por: Ribero, Simone, et al.
Publicado: (2016)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
por: Pires da Silva, Ines, et al.
Publicado: (2022)

Immunotherapy in transplanted patients: A special population that can no longer be ignored
por: Rubatto, Marco, et al.
Publicado: (2021)

Primary cutaneous lymphoma patients seen at a referral dermatological centre in 1 year: A single‐centre observational retrospective cohort study of the diagnoses and staging, comorbidities and associated symptoms, treatment performed and clinical course
por: Macagno, N., et al.
Publicado: (2022)

Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
por: Ryu, Sunhyo, et al.
Publicado: (2017)

Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives
por: Roccuzzo, Gabriele, et al.
Publicado: (2021)

Evolution of different clinical patterns of cutaneous lesions in a suspected COVID-19 patient
por: Quaglino, Pietro, et al.
Publicado: (2021)

Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19
por: Pala, Laura, et al.
Publicado: (2020)

BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report
por: Giovannoni, Sara, et al.
Publicado: (2015)

Fibroblasts Influence Metastatic Melanoma Cell Sensitivity to Combined BRAF and MEK Inhibition
por: Morales, Delphine, et al.
Publicado: (2021)

Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma
por: Hui, Caressa, et al.
Publicado: (2022)

Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
por: Dixon-Douglas, Julia R., et al.
Publicado: (2022)

Alopecia areata after COVID-19 vaccination
por: Gallo, Giuseppe, et al.
Publicado: (2022)

The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma
por: Mezi, Silvia, et al.
Publicado: (2023)

Tumoral melanosis associated with combined BRAF/MEK inhibition (dabrafenib/trametinib) in metastatic melanoma
por: Laino, Antonia, et al.
Publicado: (2018)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Sézary Syndrome: Different Erythroderma Morphological Features with Proposal for a Clinical Score System
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Sentinel Lymph Node Biopsy in Malignant Melanoma of the Head and Neck: A Single Center Experience
por: Rubatto, Marco, et al.
Publicado: (2023)

Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
por: Rubatto, Marco, et al.
Publicado: (2021)

Addendum: Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
por: Rubatto, Marco, et al.
Publicado: (2022)

CD38 Expression by Circulating and Skin-Infiltrating Lymphocytes from Sezary Syndrome Patients: A Flow Cytometry and Immunohistochemistry Study
por: Quaglino, Pietro, et al.
Publicado: (2022)

Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
por: Huynh, Sandra, et al.
Publicado: (2020)

Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib
por: Gavric, Ana Ursula, et al.
Publicado: (2018)

Comprehensive Clinical Trial Data Summation for BRAF‐MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma
por: Luke, Jason J.
Publicado: (2019)

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
por: Nepote, Alessandro, et al.
Publicado: (2022)

Nutritional Interventions for Patients with Melanoma: From Prevention to Therapy—An Update
por: Pellegrini, Marianna, et al.
Publicado: (2021)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population
por: Mastorino, Luca, et al.
Publicado: (2022)

Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients
por: Yan, Chi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kgtpi5kb5n6ahds5jdea4f180i